



- (51) **International Patent Classification:**
C07F 15/00 (2006.01) *H01L 51/50* (2006.01)
- (21) **International Application Number:**
PCT/EP20 13/002324
- (22) **International Filing Date:**
2 August 2013 (02.08.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
12 179 056.2 2 August 2012 (02.08.2012) EP
- (71) **Applicant (for DE only):** **ROCHE DIAGNOSTICS GMBH** [DE/DE]; Sandhofer StraBe 116, 68305 Mannheim (DE).
- (71) **Applicant (for all designated States except DE, US):** **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).
- (71) **Applicant:** **WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER** [DE/DE]; Schlossplatz 2, 48149 Munster (DE).
- (71) **Applicant (for US only):** **ROCHE DIAGNOSTICS OPERATIONS, INC.** [US/US]; 9115 Hague Road, Indianapolis, IN 46250-0457 (US).
- (72) **Inventors:** **CYSEWSKI, Robert**; Broniewskiego 2A, PL-89620 Chojnice (PL). **DE COLA, Luisa**; 5a Boulevard du President Edwards, F-67000 Strasbourg (FR). **FERNANDEZ HERNANDEZ, Jesus Miguel**; Frauenstr. 28, 48143 Munster (DE). **JOSEL, Hans-Peter**; Ulmenstr. 28, 82362

Weilheim (DE). **LONGHI, Elena**; Via G. Oberdan 22, I-23897 Vigano, Lecco (IT). **VONDENHOFF, Gaston Hubertus Maria**; Frauenschuhstr. 28, 82377 Penzberg (DE).

(74) **Agent:** **TESCHEMACHER, Andrea**; Isenbruck Bosl Horschler, Patentanwalte, Prinzregentenstr. 68, 81675 Munchen (DE).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2014/019710 A1

(54) **Title:** NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS

(57) **Abstract:** The present invention relates to novel bis-iridium-based Ir(III) complexes, labels manufactured using these complexes and a method for producing such complexes.

August 2, 2013

Roche Diagnostics GmbH et al.

R68638PC ATE/HER/bec

New bis-iridium-complexes for manufacturing of ECL-Labels

Background of the Invention

5 The present invention relates to novel bis-iridium-complexes and their use in the manufacturing of luminescent labels, especially electrochemiluminescent labels, as well as to a method for producing ECL-labels based on such bis-iridium-complexes.

10 Electrogenerated chemiluminescence (also called electrochemiluminescence and abbreviated ECL) is the process whereby species generated at electrodes undergo high-energy electron-transfer reactions to form excited states that emit light. The first detailed ECL studies were described by Hercules and Bard et al. in the mid-1960s. After about 50 years of study, ECL has now become a very powerful analytical technique and is widely used in the areas of, for example, immunoassay, food and water testing, and biowarfare agent detection.

15 There is a tremendous number of compounds that appears to be of interest for use in organic light emitting devices (OLEDs). These compounds are appropriate for use in solid materials or may be dissolved in organic fluids. However, no conclusion can be drawn regarding their utility in an aqueous medium as e.g., required for detection of an analyte from a biological sample.


20 In general ECL-based detection methods are based on the use of water-soluble ruthenium complexes, comprising Ru(II+) as metal ion.

Despite significant improvements made over the past decades, still a tremendous need exists for more sensitive electrochemiluminescence-based in vitro diagnostic assays.

25 It has now been surprisingly found that certain iridium-based Ir(III+) luminescent complexes, represent very promising labels for future high sensitive ECL-based detection methods and that novel bis-iridium-complexes, as disclosed herein below, can be used with great advantage to manufacture such ECL-labels.

Summary of the Invention

The present invention discloses an iridium-based chemiluminescent compound of Formula I



5 wherein each X is independently chloro, bromo, iodo, hydroxyl, methoxy, ethoxy, phenoxy, cyanato or diphenylphosphanyl,

wherein each R1-R12 independently is hydrogen, halide, cyano- or nitro-group, amino, substituted amino, alkylamino, substituted alkylamino, arylamino, substituted arylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfinio, sulfeno, sulfonate, sulfmate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl, phosphonate, phosphinate or
 10 R13, wherein R13 is aryl, substituted aryl, alkyl, substituted alkyl, branched alkyl, substituted branched alkyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino-alkyl, substituted amino-alkyl, amino-alkoxy, substituted amino-alkoxy, amino-aryl, substituted amino-aryl, amino-aryloxy, substituted amino-aryloxy,

20 wherein within R1-R12 two adjacent Rs can form an aromatic ring or a substituted aromatic ring, wherein the substituent is selected from hydrogen, alkyl, substituted

alkyl, halide, cyano- or nitro-group, a hydrophilic group, like amino, substituted amino, alkylamino, substituted alkylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfinato, sulfenato, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate or,

wherein within R1-R12 two adjacent Rs can form an aliphatic ring or a substituted aliphatic ring, wherein the substituent is selected from hydrogen, alkyl, substituted alkyl, halide, cyano- or nitro-group, a hydrophilic group, like amino, substituted amino, alkylamino, substituted alkylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfinato, sulfenato, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate,

wherein, if in any of R1-R13 a substitution is present, the substituent in R1-R13 is each independently selected from a halide, cyano- or nitro-group, a hydrophilic group, like an amino, alkylamino, alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, alkyloxy, arylalkyloxy, aryloxy, alkylaryloxy, polyethylenoxy, polypropylenoxy, sulfanyl, alkylsulfonyl, arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfinato, sulfenato, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate,

wherein alkyl is a linear or branched alkyl chain with a length of 1-20 carbon atoms or a heteroalkyl chain with the length of 1-20 atoms comprising 1-4 heteroatoms selected from O, N, P, and S, wherein aryl is a 5, 6, or 7 member aryl ring system, or a 5, 6, or 7 member heteroaryl ring system comprising 1-3 heteroatoms selected from O, S and N,

with the proviso that at least one of R1-R12 is sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, sulfino-alkyl, sulfino-aryl, sulfino-alkoxy, sulfino-aryloxy, sulfino, sulfeno-alkyl, sulfeno-aryl, sulfeno-alkoxy, sulfeno-aryloxy, sulfeno,

5 sulfamoyl-alkyl, sulfamoyl-aryl, sulfamoyl-alkoxy, sulfamoyl-aryloxy, sulfamoyl, alkanesulfonyl-alkyl, alkanesulfonyl-aryl, alkanesulfonyl, arenesulfonyl-alkyl, or arenesulfonyl-aryl, or arenesulfonyl, sulfoamino-alkyl, sulfoamino-aryl, sulfoamino-alkoxy, sulfoamino-aryloxy, sulfoamino, sulfinoamino-alkyl, sulfinoamino-aryl, sulfinoamino-alkoxy, sulfinoamino-aryloxy, sulfinoamino, alkanesulfonylamino-alkyl, alkanesulfonylamino-aryl, alkanesulfonylamino-alkoxy, alkanesulfonylamino-aryloxy, alkanesulfonylamino, arenesulfonylamino-alkyl, arenesulfonylamino-aryl, arenesulfonylamino-alkoxy, arenesulfonylamino-aryloxy, arenesulfonylamino, alkanesulfinylamino-alkyl, alkanesulfinylamino-aryl, alkanesulfinylamino-alkoxy, alkanesulfinylamino-aryloxy, alkanesulfinylamino, arenesulfinylamino-alkyl, arenesulfinylamino-aryl, arenesulfinylamino-alkoxy, arenesulfinylamino-aryloxy, arenesulfinylamino, phosphono-alkyl, phosphono-aryl, phosphono-alkyloxy, phosphono-aryloxy, phosphono, hydroxyphosphinoyl-alkyl, hydroxyphosphinoyl-aryl, hydroxyphosphinoyl-alkyloxy, hydroxyphosphinoyl-aryloxy, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl-alkyl, hydroxy-alkyl-phosphinoyl-aryl, hydroxy-alkyl-phosphinoyl-alkyloxy, hydroxy-alkyl-phosphinoyl-aryloxy, hydroxy-alkyl-phosphinoyl, phosphonoamino-alkyl, phosphonoamino-aryl, phosphonoamino-alkoxy, phosphonoamino-aryloxy, phosphonoamino, or, where chemically matching, a salt of the above described substituents.

25 The present invention further relates to the use of a compound as disclosed in the present invention in the manufacturing of a luminescent compound based on iridium³⁺. Further, the present invention discloses a method for producing an electrochemiluminescent compound.


25

Detailed Description of the Invention

As indicated above, there is a need for novel bis-iridium-complexes that can be used for manufacturing electrochemiluminescent labels (ECL-labels).

Novel bis-iridium-complexes of Formula I

30 The present invention relates to an iridium-based chemiluminescent compound of Formula I



wherein each X is independently chloro, bromo, iodo, hydroxyl, methoxy, ethoxy, phenoxy, cyanato or diphenylphosphanyl,

- 5 wherein each R1-R12 independently is hydrogen, halide, cyano- or nitro-group, amino, substituted amino, alkylamino, substituted alkylamino, arylamino, substituted arylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted
- 10 alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfmate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl, phosphonate, phosphinate or R13, wherein R13 is aryl, substituted aryl, alkyl, substituted alkyl, branched alkyl, substituted branched alkyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted
- 15 alkylaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino-alkyl, substituted amino-alkyl, amino-alkoxy, substituted amino-alkoxy, amino-aryl, substituted amino-aryl, amino-aryloxy, substituted amino-aryloxy,

wherein within R1-R12 two adjacent Rs can form an aromatic ring or a substituted aromatic ring, wherein the substituent is selected from hydrogen, alkyl, substituted

20 alkyl, halide, cyano- or nitro-group, a hydrophilic group, like amino, substituted amino, alkylamino, substituted alkylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy,

substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfonate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate or,

wherein within R1-R12 two adjacent Rs can form an aliphatic ring or a substituted aliphatic ring, wherein the substituent is selected from hydrogen, alkyl, substituted alkyl, halide, cyano- or nitro-group, a hydrophilic group, like amino, substituted amino, alkylamino, substituted alkylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfmate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate,

wherein, if in any of R1-R13 a substitution is present, the substituent in R1-R13 is each independently selected from a halide, cyano- or nitro-group, a hydrophilic group, like an amino, alkylamino, alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, alkyloxy, arylalkyloxy, aryloxy, alkylaryloxy, polyethylenoxy, polypropylenoxy, sulfanyl, alkylsulfonyl, arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfmate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate,

wherein alkyl is a linear or branched alkyl chain with a length of 1-20 carbon atoms or a heteroalkyl chain with the length of 1-20 atoms comprising 1-4 heteroatoms selected from O, N, P, and S, and, wherein aryl is a 5, 6, or 7 member aryl ring system, or a 5, 6, or 7 member heteroaryl ring system comprising 1-3 heteroatoms selected from O, S and N,

with the proviso that at least one of R1-R12 is a substituted or unsubstituted group selected from sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, sulfino-alkyl, sulfmo-aryl, sulfino-alkoxy, sulfino-aryloxy, sulfino, sulfeno-alkyl, sulfeno-aryl, sulfeno-alkoxy, sulfeno-aryloxy, sulfeno, sulfamoyl-alkyl, sulfamoyl-aryl, sulfamoyl-alkoxy, sulfamoyl-aryloxy, sulfamoyl, alkanesulfonyl-alkyl, alkanesulfonyl-aryl, alkanesulfonyl, arenesulfonyl-alkyl, or arenesulfonyl-aryl, or

5 arenesulfonyl, sulfoamino-alkyl, sulfoamino-aryl, sulfoamino-alkoxy, sulfoamino-aryloxy, sulfoamino, sulfinoamino-alkyl, sulfinoamino-aryl, sulfinoamino-alkoxy, sulfinoamino-aryloxy, sulfmoamino, alkanesulfonylamino-alkyl, alkanesulfonylamino-aryl, alkanesulfonylamino-alkoxy, alkanesulfonylamino-aryloxy, alkanesulfonylamino, arenesulfonylamino-alkyl, arenesulfonylamino-aryl, arenesulfonylamino-alkoxy, arenesulfonylamino-aryloxy, arenesulfonylamino, alkanesulfinylamino-alkyl, alkanesulfinylamino-aryl, alkanesulfinylamino-alkoxy, alkanesulfinylamino-aryloxy, alkanesulfinylamino, arenesulfinylamino-alkyl, arenesulfinylamino-aryl, arenesulfinylamino-alkoxy, arenesulfinylamino-aryloxy, arenesulfinylamino, phosphono-alkyl, phosphono-aryl, phosphono-alkyloxy, phosphono-aryloxy, phosphono, hydroxyphosphinoyl-alkyl, hydroxyphosphinoyl-aryl, hydroxyphosphinoyl-alkyloxy, hydroxyphosphinoyl-aryloxy, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl-alkyl, hydroxy-alkyl-phosphinoyl-aryl, hydroxy-alkyl-phosphinoyl-alkyloxy, hydroxy-alkyl-phosphinoyl-aryloxy, hydroxy-alkyl-phosphinoyl, phosphonoamino-alkyl, phosphonoamino-aryl, phosphonoamino-alkoxy, phosphonoamino-aryloxy, phosphonoamino, or, where chemically matching, a salt of the above described substituents.

20 The compound according to Formula I is referred to herein as bis-iridium complex or as iridium dimer (complex). It is a dinuclear (iridium) complex and it is also named a di-iridium complex.

As defined above each the two "bridging groups" X in Formula I independently is chloro, bromo, iodo, hydroxyl, methoxy, ethoxy, phenoxy, cyanato or diphenylphosphanyl.

25 In one embodiment each of the two "bridging groups" X in Formula I independently is selected from the group consisting of chloro, bromo, iodo, hydroxyl, methoxy, and cyanato.

In one embodiment each of the two "bridging groups" X in Formula I independently is selected from the group consisting of chloro, bromo and iodo.

30 In one embodiment each of the two "bridging groups" X in Formula I is chloro.

As the skilled person will appreciate, in certain embodiments the two "bridging groups" X in Formula I will be the same and as defined above.

In one embodiment, if in any of R1-R13 a substitution is present, the substituent in R1-R13 is each independently selected from a halide, cyano- or nitro-group, a hydrophilic group, like an amino, alkylamino, alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, alkyloxy, arylalkyloxy, 5 arylalkoxy, alkylaryloxy, polyethylenoxy, polypropylenoxy, sulfanyl, alkylsulfonyl, arylsulfonyl, sulfo, sulfonate, and phosphono. In one embodiment, if in any of R1-R13 a substitution is present, the substituent in R1-R13 is each independently selected from a halide, amino, carboxy, carboxylate, carboxylic acid ester, hydroxy, alkyloxy, polyethylenoxy, alkylsulfonyl, sulfo and sulfonate.

10 In one embodiment, if in any of R1-R13 a substitution is present, the substituent in R1-R13 is each independently selected from amino, carboxy, hydroxy, and sulfo and sulfonate.

In one embodiment, in none of R1-R13 a substitution is present.

15 As used herein, including the accompanying claims, the substituents have the meanings commonly known to the skilled person.

Alkyl, preferably, is a linear or branched alkyl chain with a length of 1-20 carbon atoms, preferably with a length of 1-10 carbon atom, particular preferred with a length of 1-6 carbon atoms; or a heteroalkyl chain with the length of 1-20 atoms, preferably with a length of 1-10 carbon atom, comprising 1-4 heteroatoms selected 20 from O, N, P, and S. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls, the isomeric octyls, and dodecyl. In a particular preferred embodiment, alkyl is methyl or ethyl.

25 The terms alkoxy and alkyloxy as well as substituted alkyl and substituted alkoxy, respectively, may be used interchangeably. Alkoxy and alkyloxy mean a moiety of the formula -OR, wherein R preferably is an alkyl moiety as defined hereinabove. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, and isopropoxy.

30 Aryl, preferably, is a 5, 6, or 7 member aryl ring system, preferably a 6 member aryl ring system, or a 5, 6, or 7 member heteroaryl ring system comprising 1-3 heteroatoms selected from O, S and N, preferably a 6 member heteroaryl ring system. In a particular preferred embodiment, aryl is phenyl.

- In one embodiment, in Formula I each R1-R12 independently is hydrogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfmate, sulfenate, sulfamoyl or sulfoxide.
- 5 In one embodiment, in Formula I each R1-R12 independently is hydrogen, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfonate, sulfinate, sulfenate, sulfamoyl or sulfoxide.
- In one embodiment, in Formula I each R1-R12 independently is hydrogen,
10 substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfonate or sulfoxide.
- In one embodiment, in Formula I each R1-R12 independently is hydrogen, unsubstituted alkyloxy, unsubstituted alkylsulfonyl, unsubstituted arylsulfonyl, sulfonate or sulfoxide.
- 15 In one embodiment at least one of R1 to R12 is a substituted or unsubstituted group selected from sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, sulfamoyl-alkyl, sulfamoyl-aryl, sulfamoyl-alkoxy, sulfamoyl-aryloxy, sulfamoyl, alkanesulfonyl-alkyl, alkanesulfonyl-aryl, alkanesulfonyl, arenesulfonyl-alkyl, arenesulfonyl-aryl, arenesulfonyl, alkanesulfonylamino-alkyl,
20 alkanesulfonylamino-aryl, alkanesulfonylamino-alkoxy, alkanesulfonylamino-aryloxy, alkanesulfonylamino, arenesulfonylamino-alkyl, arenesulfonylamino-aryl, arenesulfonylamino-alkoxy, arenesulfonylamino-aryloxy, arenesulfonylamino, phosphono-alkyl, phosphono-aryl, phosphono-alkyloxy, phosphono-aryloxy, phosphono, hydroxyphosphinoyl-alkyl, hydroxyphosphinoyl-aryl,
25 hydroxyphosphinoyl-alkyloxy, hydroxyphosphinoyl-aryloxy, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl-alkyl, hydroxy-alkyl-phosphinoyl-aryl, hydroxy-alkyl-phosphinoyl-alkyloxy, hydroxy-alkyl-phosphinoyl-aryloxy, hydroxy-alkyl-phosphinoyl, or, where chemically matching, a salt of the above described substituents.
- 30 In one embodiment at least one of R1 to R12 is a substituted or unsubstituted group selected from sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, or a salt thereof (=sulfonate), wherein the counter ion preferably is a cation from the group of alkali metals.

In one embodiment at least one of R1 to R12 is sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, or a salt thereof (=sulfonate), wherein the counter ion preferably is a cation from the group of alkali metals.

5 In one embodiment at least one of R1 to R12 is a substituted or unsubstituted group selected from sulfo-alkyl, sulfo-alkoxy, sulfo, or a salt thereof (=sulfonate), wherein the counter ion is a cation from the group of alkali metals.

In one embodiment at least one of R1 to R12 is sulfo-alkyl, sulfo-alkoxy, sulfo, or a salt thereof (=sulfonate), wherein the counter ion is a cation from the group of alkali metals.

10 In one embodiment at least one of R1 to R12 is sulfo-methyl, sulfo-alkoxy with a C2 to C4 alkyl chain, or a salt thereof (=sulfonate) wherein the counter ion is a cation from the group of alkali metals.

In one embodiment at least one of the groups R1 to R12 of Formula I is a sulfo group.

15 In one embodiment, the counter ion is an alkali metal cation selected from the group consisting of lithium cation, sodium cation, potassium cation and caesium cation.

In one embodiment, the counter ion is an alkali metal cation selected from the group consisting of sodium cation and caesium cation.

20 In one embodiment, the counter ion is a caesium cation.

In one embodiment, in Formula I each of the two "bridging groups" X independently is selected from the group consisting of chloro, bromo, iodo, hydroxyl, methoxy, and cyanato,

25 each R1-R12 independently is hydrogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfinate, sulfenate, sulfamoyl or sulfoxide,


30 if in any of R1-R12 a substitution is present, the substituent in R1-R13 is each independently selected from a halide, cyano- or nitro-group, a hydrophilic group, like an amino, alkylamino, alkylammonium, carboxy, carboxylate, carboxylic acid

- 11 -


ester, carbamoyl, hydroxy, alkyloxy, arylalkyloxy, aryloxy, alkylaryloxy, polyethylenoxy, polypropylenoxy, sulfanyl, alkylsulfonyl, arylsulfonyl, sulfo, sulfonate, and phosphono, and

5 at least one of R1 to R12 is a substituted or unsubstituted group selected from sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, or a salt thereof (=sulfonate), wherein the counter ion preferably is a cation from the group of alkali metals.

In one embodiment the phenyl-phenanthridine residues comprised in Formula I are selected from the below given substituted phenyl-phenanthridines.



10



5 In one embodiment, the phenyl-phenanthridine residues comprised in Formula I are selected from the substituted phenyl-phenanthridines depicted above and X is chloro.

Any combinations of any embodiments of the compounds of Formula I as defined above are considered to be within the scope of the invention.

Process for the Preparation of the novel Bis-iridium-complexes of Formula I

10 The invention, in another aspect, relates to a novel process for the preparation of compounds of Formula I.

Compounds according to Formula I can e.g. be synthesized (based on Nonoyama, M., J. Organomet. Chem. 86 (1975) 263-267) as follows and as e.g. shown in Example 3.

15 Thus, in one aspect, the invention relates to a process for the preparation of a compound of Formula I as defined above, comprising the following step:

Reaction of a phenyl-phenanthridine residue as defined above via the compound of Formula I with a iridium trihalogenide, preferably with iridium trichloride trihydrate, if appropriate in the presence of a solvent, to obtain a compound of
20 Formula I as defined above.


If the process is carried out in the presence of a solvent, suitable solvents for carrying out the process of the invention may include organic solvents. These preferably include 2-ethoxyethanol or methoxyethanol, and mixtures thereof with water ; a 2-ethoxyethanol/water mixture is preferred.

5 In one embodiment, the process is carried out in a 2-ethoxyethanol/water mixture.

In one embodiment, the process is carried out in the presence of an inorganic or organic base. This preferably include a trialkylamine base.

In one embodiment, the process is carried out under inert gas atmosphere, preferably under nitrogen.

10 In accordance with this process a compound of Formula I can be e.g. obtained as shown in Scheme 1 below.



Scheme 1: Synthesis of a compound of Formula I.

The phenyl-phenanthridines, e.g. sulfonate substituted phenyl-phenanthridines, used as starting material can be obtained by processes as e.g. shown in the Examples (cf. Examples 3.1 and 3.3).

5 The compound (4-phenanthridin-6-yl-phenyl)-methanesulfonic acid isobutyl ester is novel and also subject-matter of the present invention

Use of the Bis-iridium-complexes of the Invention for Manufacturing electrochemiluminescent Labels (ECL-labels)

10 In one aspect, the compound according to Formula I, i.e. the iridium dimer complex comprising four times a phenyl-phenanthridine derivative and two iridium 3+ atoms, is used in the manufacturing of a luminescent label. As the skilled person will appreciate such a label is a monomer or monomelic Ir³⁺ complex and comprises twice a phenyl-phenanthridine derivative as defined via Formula I and a third ligand. Preferably the resulting luminescent label is an
15 electrochemiluminescent label.


The third ligand strongly influences the light emission properties of the resulting iridium-label.

In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label, wherein the
20 third ligand is selected from the group consisting of a derivative of picolinic acid, a derivative of azolyl pyridine, a derivative of bipyridyl, a derivative of phenylpyridine, and a derivative of phenylazole.

In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label comprising
25 twice a phenyl-phenanthridine derivative as defined via Formula I and a derivative of picolinic acid as the third ligand, as described e.g. in EP 12179048.9.

A "derivative of picolinic acid" is defined by Formula II

FORMULA II



wherein R1 to R4 are as defined above for R1 to R12 of Formula I with the proviso that at least one of R1 to R4 is -Q-Z, wherein Q is a linker or a covalent bond, and wherein Z is a functional group.

- 5 Preferred embodiments of R1 to R4 are as defined above for R1 to R12 of Formula I.


Preferred embodiments of Q and Z, respectively, are defined below.

- 10 In one embodiment, one of R1 to R4 is -Q-Z, wherein Q is a linker or a covalent bond, and wherein Z is a functional group, and the other groups R1 to R4 are hydrogen.

In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label comprising twice a phenyl-phenanthridine derivative as defined via Formula I and a derivative of azolyl pyridine as the third ligand, as e.g. described in EP 12179050.5.

- 15 A "derivative of azolyl pyridine" is defined by Formula III

FORMULA III



wherein X represents C or N,

- 16 -

wherein Y represents C or N,

wherein R1 to R6 are as defined above for R1 to R12 of Formula I with the proviso that at least one of R1 to R6 is -Q-Z,

wherein Q is a linker or a covalent bond, and

5 wherein Z is a functional group.

Preferred embodiments of R1 to R6 are as defined above for R1 to R12 of Formula I.


Preferred embodiments of Q and Z, respectively, are defined below.

10 In one embodiment, one of R1 to R6 is -Q-Z, wherein Q is a linker or a covalent bond, and wherein Z is a functional group, and the other groups R1 to R6 are hydrogen.

In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label comprising twice a phenyl-phenanthridine derivative as defined via Formula I and a derivative of bipyridyl as the third ligand, as e.g. described in EP 12179054.7.

A "derivative of bipyridyl" is defined in Formula IV

FORMULA IV



wherein R1 to R8 are as defined above for R1 to R12 of Formula I with the proviso that at least one of R1 to R8 is -Q-Z,

20 wherein Q is a linker or a covalent bond, and

wherein Z is a functional group.

Preferred embodiments of R1 to R8 are as defined above for R1 to R12 of Formula I.


Preferred embodiments of Q and Z, respectively, are defined below.

- 5 In one embodiment, one of R1 to R8 is -Q-Z, wherein Q is a linker or a covalent bond, and wherein Z is a functional group, and the other groups R1 to R8 are hydrogen.

10 In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label comprising twice a phenyl-phenanthridine derivative as defined via Formula I and a derivative of phenyl-pyridine as the third ligand, as e.g. described in EP 12179054.7.

A "derivative of phenyl-pyridine" is defined in Formula V

FORMULA V



wherein in one of X and Y is N and the other is C,

- 15 wherein R1 to R8 are as defined above for R1 to R12 of Formula I with the proviso that at least one of R1 to R8 is -Q-Z,

wherein Q is a linker or a covalent bond, and

wherein Z is a functional group.

20 Preferred embodiments of R1 to R8 are as defined above for R1 to R12 of Formula I.


Preferred embodiments of Q and Z, respectively, are defined below.

In one embodiment, one of R1 to R8 is -Q-Z, wherein Q is a linker or a covalent bond, and wherein Z is a functional group, and the other groups R1 to R8 are hydrogen.


- 5 In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label comprising twice a phenyl-phenanthridine derivative as defined via Formula I and a derivative of phenylazolyne as the third ligand, as e.g. described in EP 12179057.0.

A "derivative of phenylazolyne" is defined in Formulae Via and VIb

10 FORMULAE Via and VIb



Via



VIb

- 15 wherein X and Y are C-R6 and C-R7, respectively, or wherein one of X and Y is N and the other is C-R7 or C-R6, respectively,

wherein R1 to R7 are as defined above for R1 to R12 of Formula I with the proviso that at least one of R1 to R7 is -Q-Z,

wherein Q is a linker or a covalent bond, and

wherein Z is a functional group.

- 20 Preferred embodiments of R1 to R7 are as defined above for R1 to R12 of Formula I.

Preferred embodiments of Q and Z, respectively, are defined below.

In one embodiment, one of R1 to R7 is -Q-Z, wherein Q is a linker or a covalent bond, and wherein Z is a functional group, and the other groups R1 to R7 are hydrogen.

5 In one embodiment the present invention relates to the use of a bis-iridium complex according to Formula I in the manufacturing of a luminescent label, wherein the third ligand is selected from the group consisting of a derivative of picolinic acid, a derivative of azolyl pyridine, a derivative of bipyridyl, and a derivative of phenylpyridine.

10 In the compounds according Formulas II, III, IV, V and VI, respectively, Q either is a covalent bond or a linker having a backbone length of between 1 and 200 atoms. With other words if the backbone length is between 1 and 200 atoms, the shortest connection between the aromatic ring of a ligand according to any of Formulas II, III, IV, V, and VI, respectively, and the functional group Z consists of
15 1 to 200 atoms.

In case a ring system is present the shortest number of atoms in the ring system is taken when assessing the linker length. As an example, a phenylene ring accounts for a length of four atoms in a linker.

20 In one embodiment Q is a covalent bond or a linker having as a backbone a straight or branched saturated, unsaturated, unsubstituted or substituted C1-C200 alkyl chain, or a 1 to 200 atom chain consisting of carbon atoms, substituted carbon atoms and/or one or more atoms selected from O, N, P and S, or substituted N, P, S atoms, or a chain as described before with the backbone containing one or more cyclic or heterocyclic aromatic or non-aromatic ring systems.

25 In one embodiment the linker Q has as a backbone a straight or branched saturated, unsaturated, unsubstituted or substituted C1-C100 alkyl chain, or a 1 to 100 atom chain consisting of carbon atoms, substituted carbon atoms and/or one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms, or a chain as described before with the backbone containing one or more cyclic or heterocyclic
30 aromatic or non-aromatic ring systems.

In one embodiment the linker Q has as a backbone a straight or branched saturated, unsaturated, unsubstituted or substituted C1-C50 alkyl chain, or a 1 to 50 atom

chain consisting of carbon atoms, substituted carbon atoms and/or one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms, or a chain as described before with the backbone containing one or more cyclic or heterocyclic aromatic or non-aromatic ring systems.

5 In one further embodiment the linker Q has as a backbone a straight or branched saturated, unsaturated, unsubstituted or substituted C1-C20 alkyl chain, or a 1 to 20 atom chain consisting of carbon atoms, substituted carbon atoms and/or one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms, or a chain as described before with the backbone containing one or more cyclic or
10 heterocyclic aromatic or non-aromatic ring systems.

In one embodiment, the linker Q in the electrochemiluminescent complex of this invention is a straight or branched saturated, unsaturated, unsubstituted, substituted C1-C20 alkyl chain, or a C1-C20 arylalkyl chain (wherein e.g. a phenylene ring accounts for a length of four carbon atoms), or a 1 to 20 atom chain with a
15 backbone consisting of carbon atoms, substituted carbon atoms and/or one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms, or a 1 to 20 atom chain, or with a backbone consisting of carbon atoms, substituted carbon atoms and one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms comprising at least one aryl, heteroaryl, substituted aryl or substituted
20 heteroaryl group (wherein e.g. a phenylene ring accounts for a length of four atoms).

In one embodiment the linker Q in a compound according to the present invention is a saturated C1-C12 alkyl chain, or a C1-C12 arylalkyl chain, or a 1 to 12 atom chain with a backbone consisting of carbon atoms, substituted carbon atoms and
25 one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms, or a 1 to 12 atom chain with a backbone consisting of carbon atoms, substituted carbon atoms and one or more atoms selected from O, N, P and S, or substituted N, P, or S atoms comprising at least one aryl, heteroaryl, substituted aryl or substituted
30 heteroaryl group (wherein e.g. a phenylene ring accounts for a length of four atoms).

The term "linker" as used herein, has the meaning known to a person skilled in the art and relates to a molecule or groups of molecules, which are used to link fragments of molecules. Linkers are characterized by having two or more chemically orthogonal functionalities on a flexible or rigid scaffold.

In one embodiment one of R1 to R4 of Formula II, or one of R1 to R6 of Formula III, or one of R1 to R8 of Formula IV, or one of R1 to R8 of Formula V, or one of R1 to R7 of Formula VI, respectively is -Q-Z.

5 In one embodiment the functional group Z comprised in the third ligand according to Formulas II, III, IV, V, or VI, respectively, is selected from the group consisting of aldehyde, carboxylic acid, carboxylic acid ester, N-hydroxysuccinimide ester, epoxide, amino group, halogen, hydrazine, hydroxyl, sulfhydryl, maleimido, alkynyl, azide and phosphoramidite.

10 In one embodiment the functional group Z comprised in the third ligand according to Formulas II, III, IV, V, or VI, respectively, is selected from the group consisting of carboxylic acid, amino group, halogen, sulfhydryl, maleimido, alkynyl and azide.

Methods for producing electrochemiluminescent compounds and labels

15 Further the present invention discloses a method for producing an electrochemiluminescent compound the method comprising the reaction of a dimer as described above with a third ligand, e.g. with a third ligand as described above, in an organic solvent in the presence or absence of a base under inert gas atmosphere.

20 In one embodiment the reaction of a dimer as described above with a third ligand, e.g. with a third ligand as described above, is performed in dimethylformamide (DMF) in the presence of a base under inert gas atmosphere.

In one embodiment the base used is a carbonate salt of an alkalimetal.

In one embodiment the base used is caesium carbonate.

25 As mentioned, the compounds as disclosed herein have quite favorable properties. For example the disclosed compounds, i.e., the iridium-based labels manufactured using these compounds, show a high ECL efficiency. This high efficiency is also present if the corresponding measurements are performed in an aqueous system as compared to many, many ECL-labels that only have shown high ECL-efficiency when analyzed in an organic solvent. E.g., many OLED dyes usually are analyzed
30 in acetonitrile and either are not soluble in an aqueous solution or, if soluble, do not show efficient electrochemiluminescence in an aqueous solution.

In one aspect, the present invention relates to the use of a compound of Formula I of the invention as a starting material in the manufacturing of an electrochemiluminescent label.

5 In one preferred embodiment the present invention relates to the use of a compound as disclosed in the present invention for manufacturing of a label showing an electrochemiluminescence reaction in an aqueous solution. An aqueous solution is any solution comprising at least 90% water (weight by weight). Obviously such aqueous solution may contain in addition ingredients like buffer compounds, detergents and for example tertiary amines like tripropylamine as electron donor in
10 the ECL reaction.

The following examples are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

15 All publications identified herein are incorporated herein by reference in their entirety.

Examples


20 Example 1

Synthesis of substituted phenyl-phenanthridines


Example 1.1

General procedure for the synthesis of substituted 2-aminobiphenyls:

25 With the Suzuki-Miyaura coupling reaction as described by Youn, S.W., in Tetrahedron Lett. 50 (2009) 4598-4601, between commercially available 2-bromoaniline derivatives and the corresponding arylboronic acid the appropriate 2-aminobiphenyls can be synthesized, which are required for further reactions to phenanthridines.

Typical procedure:

a: 10 mol % PdCl₂(PPh₃)₂, K₂CO₃, DMF/H₂O (5/1), 80 °C, 24 h

Other Examples:

5


Example 1.2**General procedure for the synthesis of substituted phenanthridines:**

To the ice-cooled solution of 2-arylaniline **1** (0.01 mol) in chloroform (20 ml) was added aryl acid chloride **2** (0.01 mol) and stirred under inert condition for 30 min at room temperature. The resulting mixture was refluxed with stirring for the next 2 hours. The reaction mixture was treated by the dropwise addition of pyridine (0.02 mol in 10 ml chloroform) over a period of 60 minutes. The mixture was allowed to cool to room temperature and stirred overnight. The mixture was washed well with 0.5 M HCl, dried over MgSO₄ and concentrated in vacuum. The crude product was purified by flash chromatography on silica gel, 3:2 hexane/ethyl acetate to give pure product **3** in 66% yield.

Benzamido-2-biphenyl **3** (0.01 mol) and POCl₃ (5 ml) in 20 ml of toluene were refluxed and stirred under nitrogen for 18 hours, following the procedure described by Lion, C., in Bull. Soc. Chim. Belg. 98 (1989) 557-566. The cooled reaction mixture was diluted with CH₂Cl₂ (30 ml) and poured into ice, washed with 25% NH₄OH and distilled water. The organic layer was dried over MgSO₄ and concentrated in vacuo, followed by flash chromatography (silica gel, 1:1 hexane/ethyl acetate) gave the product **4**, 6-phenylphenanthridine.


20

- 24 -



Yield: 52%. White solid. ¹H NMR (CDCl₃, 400 MHz) δ 7.54-7.85 (m, 9H), 8.10 (d, J = 8.0 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.67 (d, J = 8.4 Hz, 1H).


5 Using 2-naphthalen-2-yl-phenylamine instead of 2-aryl-aniline yields:



¹H-NMR (400 MHz, CDCl₃) δ 8.64 (d, J = 9.1 Hz, 2H), 8.29 (d, J = 8.1 Hz, 1H), 8.16 (d, J = 8.92 Hz, 1H), 7.92 (d, J = 7.48 Hz, 1H), 7.79-7.75 (m, 2H), 7.69 (t, J = 14.0, 8.2 Hz, 1H), 7.63-7.61 (m, 2H), 7.53-7.46 (m, 4H), 7.19 (t, J = 14.3, 7.2 Hz, 1H).

MS: [M+H]⁺ 306.3

15 Using naphthalene-carbonyl chloride instead of phenyl acid chloride yields:



¹H-NMR (400 MHz, CDCl₃) δ 8.74 (d, J = 8.3 Hz, 1H), 8.65 (d, J = 8.1 Hz, 1H), 8.27 (d, J = 8.1 Hz, 1H), 8.23 (s, 1H), 8.15 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.97-7.94 (m, 2H), 7.90-7.85 (m, 2H), 7.80-7.69 (m, 2H), 7.62 (t, J = 14.2, 7.1 Hz, 1H), 7.59-7.55 (m, 2H).


5 MS: [M+H]⁺ 306.3

Example 1.3

Procedure for the synthesis of 6-(2-sulfophenyl) phenanthridine

10 The 6-(2-sulfophenyl)phenanthridine can be synthesized by gentle heating of arylaniline (0.01 mol) with 2-sulfobenzoyl cyclic anhydride (0.01 mol) in CH₃CN for 6 hours using the procedure as described by Nicolai, E., in Chem. Pharm. Bull. 42 (1994) 1617-1630.

After purification the product can be converted to the appropriate phenanthridine based on the method described in example 1.2.




Example 1.4

Procedure for the synthesis of 6-phenyl-alkylsulfonyl phenanthridine

20 The 6-phenyl-alkylsulfonyl phenanthridine can be synthesized by gentle heating of alkylsulfonyl-arylaniline (0.01 mol) with benzoic acid chloride (0.01 mol) in chloroform using the procedure as described by Lion, C., in Bull. Soc. Chim. Belg. 98 (1989) 557-566, see example 1.2.

After purification the product can be converted to the appropriate phenanthridine based on the method described in example 1.2.




¹H-NMR (400 MHz, CDCl₃) δ 8.92 (d, J = 8.7 Hz, 1H), 8.75 (d, J = 1.9 Hz, 1H), 8.68 (d, J = 7.0 Hz, 1H), 8.35 (dd, J = 8.7, 2.0 Hz, 1H), 8.30 (d, J = 7.2 Hz, 1H), 7.89 (t, J = 15.3, 7.1 Hz, 1H), 7.81-7.73 (m, 3H), 7.64-7.56 (m, 3H) 3.12 (s, 3H).

5 **MS:** [M+H]⁺ 334,3

The 6-(4-methylsulfonylphenyl)phenanthridine can be also prepared by following the procedure described by Cymerman, J., in J. Chem. Soc. (1949) 703-707.

Example 1.5

10 **Synthesis of 6-[4-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy}-ethoxy)-phenyl]-phenanthridine**



Synthesis of 2,5,8,11-tetraoxatridecan-13-ol tosylate:

15 **Procedure:** (JACS, 2007, 129, 13364) To a solution of 2,5,8,11-tetraoxatridecan-13-ol (7 g, 33.6 mmol) and triethylamine (4.9 ml, 35.3 mmol) in dry CH₂Cl₂ (100 ml), 4-toluenesulfonyl chloride (6.7 g, 35.3 mmol) and DMAP (120 mg) were added. The mixture was stirred at room temperature for 20 h. The reaction mixture was washed with 80 mL of HCl (1M) and then water. The extract was dried over anhydrous MgSO₄, filtered, and the filtrate was evaporated. The residue was used

20 in the next step without further purification.

Yield: 11.0 g (90%)

- 27 -

NMR:

¹H NMR (400 MHz, CDCl₃) δ 7.75 - 7.64 (m, 2H), 7.31 - 7.26 (m, 2H), 4.16 - 4.06 (m, 2H), 3.62 (m 2H), 3.59 - 3.40 (m, 10H), 3.30 (s, 3H), 2.38 (s, 3H).

5 ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 144.75 (s), 132.90 (s), 129.77 (s), 127.8 (s), 71.82 (s), 70.60 (s), 70.48 (s), 70.47 (s), 70.41 (s), 70.39 (s), 69.23 (s), 68.55 (s), 58.90 (s), 21.53 (s).

Synthesis of 4-PEG4-benzoic acid ethyl ester:

Procedure: (JACS, 2007, 129, 13364) A mixture of compound ethyl 2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (8.1 g, 22.3 mmol), 4-hydroxybenzoic acid ethyl ester (3.7 g, 22.3 mmol), K₂CO₃ (15.4 g, 111.5 mmol) and 18-crown-6 (0.59 g, 2.2 mmol) was refluxed in acetone (120 ml) for 22 h. The reaction mixture was concentrated and extracted with ethyl acetate. The extract was washed with H₂O, dried over anhydrous MgSO₄, and filtrated. The filtrate was evaporated to dryness and the residue was purified by column chromatography on silica gel (dichloromethane/methanol = 100:1) to obtain the compound (1.93 g, 88%).

Yield: 7 g (88%)

NMR:

20 ¹H NMR (400 MHz, CDCl₃) δ 8.01 - 7.84 (m, 2H), 6.96 - 6.85 (m, 2H), 4.29 (q, *J* = 7.1 Hz, 2H), 4.12 (dd, *J* = 5.4, 4.3 Hz, 2H), 3.82 (dd, *J* = 5.4, 4.2 Hz, 2H), 3.71 - 3.56 (m, 10H), 3.51 - 3.45 (m, 2H), 3.32 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H).

25 ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 166.29 (s), 162.47 (s), 131.45 (s), 123.01 (s), 114.11 (s), 71.90 (s), 70.84 (s), 70.60 (s), 70.59 (s), 70.58 (s), 70.48 (s), 69.51 (s), 67.54 (s), 60.57 (s), 58.98 (s), 14.35 (s).

MS(+):

[M+Na⁺]⁺ = calc. 379.1727, found 379.1743

Synthesis of 4-PEG4-benzoic acid:

Procedure: (JACS, 2007, 129, 13364) A mixture of compound ethyl 4-(2,5,8,11-tetraoxatridecan-13-yloxy)benzoate (7 g, 19.6 mmol), and KOH (2.3 g, 41.24 mmol) in 200 mL of EtOH/H₂O (1:1 v/v) was refluxed overnight. After cooling down, the mixture was neutralized with HCl (2N). The resulting mixture was extracted with EtOAc and evaporated to dryness. The resulting white solid was recrystallized in EtOAc/hexane.

Yield: 5.3 g (85%)

NMR:

¹H NMR (300 MHz, CDCl₃) δ 11.17 (s, 1H), 8.14 - 7.89 (m, 2H), 7.03 - 6.75 (m, 2H), 4.29 - 4.02 (m, 2H), 3.92 - 3.81 (m, 2H), 3.78 - 3.57 (m, 10H), 3.57 - 3.46 (m, 2H), 3.35 (s, 3H).

¹³C{¹H} NMR (75 MHz, CDCl₃) δ 171.46 (s), 163.24 (s), 132.30 (s), 121.98 (s), 114.33 (s), 71.96 (s), 70.91 (s), 70.67 (s), 70.66 (s), 70.64 (s), 70.54 (s), 69.55 (s), 67.66 (s), 59.08 (s).

MS(-):

[M-H]⁻ = calc. 327.1438, found 327.1456

Synthesis of N-biphenyl-2-yl-4-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzamide :

Procedure: To a solution of 4-(2,5,8,11-tetraoxatridecan-13-yloxy)benzoic acid (3 g, 9.14 mmol), 0.2 mL of DMF in 30 mL dry DCM at 0°C, oxalyl chloride (1.05 mL, 12.34 mmol) was added. The reaction mixture was stirred at 0°C for 1 h. The solution was concentrated to dryness. The oily residue was used without further purification in the next step.

A solution of 2-phenylaniline (1.6 g), pyridine (2.4 mL) in chloroform (80 mL) under inert atmosphere was cooled down to 0 °C. (phenyl-4-(2,5,8,11-tetraoxatridecan-13-yloxy)benzoyl chloride (3.1 g, 9.14 mmol) in 20 mL was slowly added to the solution and the final mixture allowed to reach room temperature. The solution was refluxed for 2 h and stirred overnight at room temperature. The reaction mixture was extracted with HCl (1 M, 2 x 100 mL),

NaHCO₃ (100 mL) and water (50 mL). The organic phase was dried with MgSO₄ and purified by chromatography in silica gel (EtOAc/hexane).

Yield: 4.1 (90%)

NMR:

5 **¹H NMR** (400 MHz, CDCl₃) δ 8.49 (dd, *J* = 8.3, 0.9 Hz, 1H), 7.94 (s, 1H), 7.61 - 7.35 (m, 9H), 7.33 - 7.25 (m, 1H), 7.19 (m, 1H), 6.91 - 6.84 (m, 2H), 4.16 - 4.10 (m, 2H), 3.85 (m, 2H), 3.77 - 3.58 (m, 10H), 3.56 - 3.49 (m, 2H), 3.36 (s, 3H).

10 **¹³C{¹H} NMR** (101 MHz, CDCl₃) δ 164.56 (s), 161.65 (s), 138.18 (s), 135.12 (s), 132.32 (s), 129.97 (s), 129.39 (s), 129.22 (s), 128.66 (s), 128.57 (s), 128.16 (s), 127.13 (s), 124.18 (s), 121.23 (s), 114.57 (s), 71.95 (s), 70.89 (s), 70.64 (s), 70.63 (s), 70.54 (s), 69.54 (s), 67.63 (s), 59.04 (s), 53.51 (s).

MS(+)

[M+H]⁺ = calc. 480.2386 found. 480.2383; [M+Na]⁺ = calc. 502.2200, found 502.2204

15 **Synthesis of 6-[4-(2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy)-phenyl]-phenanthridine:**

Procedure: N-Biphenyl-2-yl-4-(2- {2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy} - ethoxy)-benzamide (4 g, 8.34 mmol), POCl₃ (10 ml) in 10 ml toluene were refluxed for 20 h. The mixture was cooled down to room temperature, and 100 ml of dichloromethane were added. The solution was poured into ice and the mixture neutralized with NH₄OH (20%). The organic phase was extracted and washed successively with distilled water and brine, and dried over MgSO₄. The resulting solution was purified by flash chromatography (silica gel, in ethyl acetate/hexane 1:1, R_f = 0.14).

25 **Yield:** 1 g (25%)

NMR:

30 **¹H NMR** (300 MHz, CDCl₃) δ 8.68 (d, *J* = 8.3 Hz, 1H), 8.59 (dd, *J* = 8.1, 1.4 Hz, 1H), 8.23 (dd, *J* = 8.1, 1.1 Hz, 1H), 8.15 (dd, *J* = 8.3, 0.7 Hz, 1H), 7.84 (ddd, *J* = 8.3, 7.1, 1.3 Hz, 1H), 7.79 - 7.57 (m, 5H), 7.15 - 7.03 (m, 2H), 4.29 - 4.19 (m, 2H), 3.93-3.90 (m, 2H), 3.80 - 3.60 (m, 12H), 3.59 - 3.49 (m, 2H), 3.37 (s, 3H).

dichloromethane and precipitated upon addition of Et₂O. It was used in the next step without further purification.

Yield: 550 mg (50%)

NMR:

5 **¹H NMR** (300 MHz, CDCl₃) δ 8.74 (d, *J* = 8.1 Hz, 4H), 8.36 (dd, *J* = 8.0, 5.2 Hz, 8H), 7.90 (dd, *J* = 14.7, 7.7 Hz, 8H), 7.81 (d, *J* = 9.0 Hz, 4H), 7.79 - 7.67 (m, 4H), 6.78 - 6.65 (m, 4H), 6.32 (dd, *J* = 8.8, 2.5 Hz, 4H), 5.89-5.83 (m, 4H), 5.28 (d, *J* = 2.5 Hz, 4H), 3.67-3.10 (m, 100H, PEG Chain, contains some impurities)

MS(ESI-MS(+)):


10 [M+2Na⁺]²⁺ calc. 1171.3463, found 1171.3473; [(C^N)₂Ir]⁺ = calc. 1113.3877, found 1113.3892

Example 3:

Synthesis of sulfonate substituted phenylphenanthridines and their use in building bis-phenylphenanthridine complexes

15 **Example 3.1**

Synthesis of 3-(4-phenanthridin-6-yl-phenoxy)-propane-1-sulfonate caesium salt



20 6-(4-Methoxyphenyl)phenanthridine was prepared by cyclisation of the N-(biphenyl-2-yl)-4-methoxybenzamide (2 g, 6.59 mmol) following the procedure as described above. The compound was purified by chromatography in dichloromethane/hexane (gradient 1:5 to 1:1). Yield: 87%.

25 **NMR :** ¹H NMR (300 MHz, DMSO) δ 8.94 (d, *J* = 8.2 Hz, 1H), 8.84 (dd, *J* = 8.2, 1.2 Hz, 1H), 8.18 - 8.05 (m, 2H), 7.97 (ddd, *J* = 8.3, 7.1, 1.3 Hz, 1H), 7.86 - 7.62 (m, 5H), 7.23 - 7.07 (m, 2H), 3.88 (s, 3H).

- 32 -

¹H NMR (300 MHz, CDCl₃) δ 8.70 (d, *J* = 8.3 Hz, 1H), 8.61 (dd, *J* = 8.1, 1.3 Hz, 1H), 8.28 (d, *J* = 8.0 Hz, 1H), 8.18 (dd, *J* = 8.3, 0.7 Hz, 1H), 7.86 (ddd, *J* = 8.3, 7.1, 1.3 Hz, 1H), 7.81 - 7.56 (m, 5H), 7.18 - 7.02 (m, 2H), 3.92 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 160.95 (s), 160.33 (s), 143.72 (s), 133.67 (s), 132.12 (s),
5 131.36 (s), 130.71 (s), 130.20 (s), 129.13 (s), 128.97 (s), 127.23 (s), 126.92 (s), 125.40 (s),
123.73 (s), 122.33 (s), 122.03 (s), 114.03 (s), 55.57 (s).

MS [ESI-MS (+)]: [M+H⁺]⁺ found 286.1231, calc. 286.1226

4-Phenanthridin-6-yl-phenol: Deprotection of the 6-(4-methoxyphenyl)phenanthridine was achieved by using HBr. A suspension of 6-(4-methoxyphenyl)phenanthridine (1 g, 3.5 mmol) in 15 mL (HBr, 47%) was refluxed
10 at 100 °C for 12h. The mixture was cooled down to room temperature, poured into ice-water and neutralized with Na₂CO₃. The resulting precipitate was filtered off and washed with water and Et₂O. The solid was purified by chromatography column using dichloromethane/MeOH. Yield: 90%.


15 NMR: **¹H NMR** (300 MHz, DMSO) δ 9.84 (s, 1H), 8.92 (d, *J* = 8.2 Hz, 1H), 8.82 (dd, *J* = 8.2, 1.2 Hz, 1H), 8.20 - 8.11 (m, 1H), 8.08 (dd, *J* = 8.1, 1.2 Hz, 1H), 8.02 - 7.88 (m, 1H), 7.84 - 7.64 (m, 3H), 7.64 - 7.49 (m, 2H), 7.06 - 6.89 (m, 2H).

MS [ESI-MS (-)]: [M-H⁺]⁻ found 270.0922, calc. 270.0924

To a solution of 4-(phenanthridin-6-yl)phenol (320 mg, 1.18 mmol) in DMF (4 ml),
20 Cs₂CO₃ (482.2 mg, 1.48 mmol) and 1,3-propylsultone (159 mg, 1.30 mmol) were added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated to dryness and the residue was purified by chromatography column (silica) using dichloromethane/MeOH (gradient 10:1 to 5:1). Yield: 72%

25 NMR: **¹H NMR** (300 MHz, DMSO-d₆) δ 8.98 - 8.87 (m, 1H), 8.83 (dd, *J* = 7.9, 1.6 Hz, 1H), 8.12 (m, 2H), 7.97 (ddd, *J* = 8.3, 7.0, 1.3 Hz, 1H), 7.85 - 7.69 (m, 3H), 7.67 (d, *J* = 8.6 Hz, 2H), 7.14 (d, *J* = 8.7 Hz, 2H), 4.19 (t, *J* = 6.5 Hz, 2H), 2.64 - 2.57 (m, 2H), 2.15 - 1.97 (m, 2H).

MS [EI-MS (-)]: [M-Cs⁺]⁻-calc 392.0956. found 392.0962


Example 3.2**Synthesis of bis-iridium complex with 3-(4-phenanthridin-6-yl-phenoxy)-propane-1-sulfonate caesium salt**

- 5 A mixture of the ligand caesium 3-(4-(phenanthridin-6-yl)phenoxy)propane-1-sulfonate (500 mg, 0.92 mmol) and IrCl₃ (159.5 mg, 0.45 mmol) in 2-ethoxyethanol:water (3:1, 16 ml) mixture, was refluxed under nitrogen atmosphere for 36 h. The reaction mixture was filtered, and the filtrate was concentrated to dryness. The residue was used for the synthesis of iridium monomer complexes
- 10 without further purification.

MS [ESI-MS(-)]: [Ir(C^N)₂-2Cs⁺] calc 975.13858, found 975.13882

Example 3.3**Synthesis of (4-phenanthridin-6-yl-phenyl)-methanesulfonic acid**

15



6-(4-Chloromethyl-phenyl)-phenanthridine:

4-Chloromethyl-benzoylchloride (2.5 g, 13.2 mmol) and 2-amino-biphenyl (1.95 g, 11.5 mmol) were dissolved in DCM (50 mL) and stirred at 45 °C for 4 h and

subsequently for another 16 h at RT under argon. To the mixture pyridine (2.4 mL) was added and the organic layer was washed with water (2 x 50 mL). The organic layer was next dried over Na_2SO_4 , filtered and evaporated, yielding 3.78 g of N-biphenyl-2-yl-4-chloromethyl-benzamide.

5 **MS [ESI-MS(+)]**: calcd for $\text{C}_{20}\text{H}_{17}\text{ClNO}$: 322, 1[M+H]⁺; found 322.3

N-Biphenyl-2-yl-4-chloromethyl-benzamide, POCl_3 (20 mL) and toluene (40 mL) were combined and stirred at 120 °C for 16 h. The reaction mixture was dried by evaporation and the residue taken up in ethylacetate (100 mL), the organic layer was then washed with NaHCO_3 (sat.) (2 x 50 mL). The organic layer was dried over
10 Na_2SO_4 , filtered and evaporated to yield 1.96 g of 6-(4-chloromethyl-phenyl)-phenanthridine .


MS [ESI-MS(+)]: calcd for $\text{C}_{20}\text{H}_{15}\text{ClN}$: 304.1[M+H]⁺; found 304.4

(4-Phenanthridin-6-yl-phenyl)-methanesulfonate sodium salt: 6-(4-chloromethyl-phenyl)-phenanthridine (1.3 g) and sodium sulfite (5 g) were dissolved in a mixture of $\text{H}_2\text{O}/\text{MeOH}$ (35/16 mL) and stirred at 100 °C for 11 h under argon atmosphere.
15 The reaction mixture was filtered and the volume reduced to 10 mL under reduced pressure. The product was subsequently precipitated by the addition of 30 mL MeOH. The product was next filtered off and washed with a mixture of $\text{MeOH}/\text{H}_2\text{O}$ (3/1, v/v). The RM was next dried under reduced pressure to yield
20 1.0 g of (4-phenanthridin-6-yl-phenyl)-methanesulfonate sodium salt.

MS [ESI-MS(+)]: calcd for $\text{C}_{20}\text{H}_{16}\text{NO}_3$: 350.1 [M+H]⁺; found 350.4

Example 3.4

Synthesis of bis-iridium complex with (4-phenanthridin-6-yl-phenyl)-methanesulfonic acid




- 35 -

(4-Phenanthridin-6-yl-phenyl)-methanesulfonic acid (50 mg) and IrCl_3 (30 mg) were dissolved in a mixture of 2-ethoxyethanol and water (3:1, v/v), to which DIPEA (25 μL) was added. The reaction mixture was stirred at 110 °C overnight under Ar. Subsequently, the mixture was cooled down to room temperature and filtered over a nitrocellulose (0.45 μm) filter, yielding a bright red solution. The volatiles were evaporated and the product purified by HPLC.

MS [ESI-MS(+)]: Calcd. for $(\text{M}-2\text{H}^+)^+$: $\text{C}_{40}\text{H}_{26}\text{IrN}_2\text{O}_6\text{S}_2$ 887.1. Found: 887.1 (= observed fragment of one iridium ion with two ligands)

10 Example 3.5

Synthesis of the sodium salt of (6-phenyl-phenanthridin-9-yl)-methanesulfonate



15 Step 1: m-tolylboronic acid (10 g, 73.55 mmol), 2-bromoaniline (15.1 g, 88.26 mmol), KF (10 g, 172 mmol), tricyclohexylphosphine (1 g, 3.56 mmol), and $\text{Pd}(\text{OAc})_2$ (260 mg, 1.15 mmol) were suspended/dissolved in dry THF (100 mL) under Ar atmosphere and stirred overnight at 80 °C.

20 Subsequently, the RM was taken up in EtOAc and washed with water (twice 100 mL). The organic layer was dried over Na_2SO_4 , filtered and the volatiles were evaporated, yielding a dark yellow oil. The product was next purified on a silica column, using a system of 5 to 15% EtOAc in petroleum ether.

Yield: 8 g (60%)

MS [ESI-MS(+)]: Calcd. for (M+H⁺): C₁₃H₁₄N 184.1 . Found: 184.2

Step 2: (8 g, 43.48 mmol) product of step 1 and benzoylchloride (5 mL (43.48 mmol) were reacted in dry DCM at room temperature under Ar atmosphere for 2 h. The volatiles were evaporated and the residue was taken up in EtOAc and washed with NaHCO₃ sat. (twice 50 mL) and once with brine. The organic layer was dried over Na₂SO₄, filtered and the volatiles were evaporated, yielding dark yellow oil. The product was next purified on a silica column, using a system of 5 to 15% EtOAc in petroleum ether. This yielded two products that could not be separated using silica chromatography.

Approximate yield: 12 g (-90%)

MS [ESI-MS(+)]: Calcd. for (M+H⁺): C₂₀H₁₈NO 288.1 Found: 288.2

Step 3: The crude product of step 2 (12 g, 45 mmol) was dissolved in toluene (100 mL), to which POCl₃ (80 mL) was added. The mixture was next stirred overnight, at 120 °C, under Ar atmosphere. Subsequently, the volatiles were evaporated and the residue was taken up in EtOAc and washed with NaHCO₃ sat. (twice 100 mL) and once with brine. The organic layer was dried over Na₂SO₄, filtered and the volatiles were evaporated, yielding dark yellow oil. The product was next purified on a silica column, using a system of 5 to 15 % EtOAc in petroleum ether. This again yielded two products that however were separated nicely using 2 % MeOH in DCM.

Approximate yield: 8 g (66 %)

MS [ESI-MS(+)]: Calcd. for (M+H⁺): C₂₀H₁₆N: 270.1 Found: 270.2

Step 4: The product of step 3 (500 mg, 1.8 mmol) was dissolved in THF (5 mL) and cooled to -78 °C under Ar atmosphere. Next, LDA (2.5 mL) was added and the mixture was stirred for 15 min at -78°C. Subsequently, chlorotrimethylsilane (0.5 mL) was added and the mixture was again stirred for another 15 min., after which the reaction was quenched with EtOH (0.6 mL). The mixture was taken up in EtOAc (50 mL) and washed with NaHCO₃ sat. (twice 20 mL) and once with brine (20 mL). The organic layer was dried over Na₂SO₄, filtered and the volatiles were evaporated, yielding dark yellow oil.

Approximate yield: 200 mg (40 %)

- 37 -

MS [ESI-MS(+)]: Calcd. for (M+H⁺): C₂₃H₂₃NSi: 342.2 Found: 342.2

Step 5: The crude product of step 5, (250 mg, 0.73 mmol), CsF (540 mg, 3.5 mmol), C₂Cl₆ (840 mg, 3.5 mmol) were dissolved/suspended in CH₃CN (5 mL) and stirred at 70 °C for 2 h under Ar atmosphere. The mixture was taken up in EtOAc (50 mL) and washed with water (20 mL) and once with brine (20 mL). The organic layer was dried over Na₂SO₄, filtered and the volatiles were evaporated, yielding pale yellow solid.


MS [ESI-MS(+)]: Calcd. for (M+H⁺): C₂₀H₁₅ClN: 304.1 Found: 304.1

Step 6: The crude product of step 5 (250 mg, 0.8 mmol) and Na₂SO₃ (200 mg, 1.5 mmol) were dissolved in a mixture of MeOH/water (10 mL, 1:1, v/v) and stirred while refluxing for 10 h. Subsequently, the volatiles were evaporated and the residue was taken up in EtOAc and water. The water layer containing the product was dried and further purified on a diaion column (2 to 20 % acetone in water, eluting the product with ~ 15 % acetone). The product was next further purified using HPLC on a preparative Vydac C-18 column in a system of 2 to 50 % CH₃CN in water.

MS [ESI-MS(+)]: Calcd. for (M+H⁺): C₂₀H₁₅ClN: 350.1 Found: 350.1

Example 3.6

The synthesis of disodium salt of (6-phenyl-2-sulfomethyl-phenanthridin-9-yl)-methanesulfonic acid




The synthesis of disodium salt of (6-phenyl-2-sulfomethyl-phenanthridin-9-yl)-methanesulfonic acid was carried out according to the procedure described in example 3.4 using the appropriate starting materials and stoichiometrics.

Roche Diagnostics GmbH et al.

August 2, 2013
R68638PC ATE/HER/bec

Claims

- 5 1. An iridium-based compound of Formula I



10 wherein each X is independently chloro, bromo, iodo, hydroxyl, methoxy, ethoxy, phenoxy, cyanato or diphenylphosphanyl,

15 wherein each R1-R12 independently is hydrogen, halide, cyano- or nitro-group, amino, substituted amino, alkylamino, substituted alkylamino, arylamino, substituted arylamino, alkylammonium, substituted alkylammonium, carboxy, carboxylate, carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate, sulfonate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl, phosphonate, phosphinate or R13, wherein R13 is aryl,

substituted aryl, alkyl, substituted alkyl, branched alkyl, substituted branched
alkyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, amino-alkyl, substituted
amino-alkyl, amino-alkoxy, substituted amino-alkoxy, amino-aryl,
5 substituted amino-aryl, amino-aryloxy, substituted amino-aryloxy,

wherein within R1-R12 two adjacent Rs can form an aromatic ring or a
substituted aromatic ring, wherein the substituent is selected from hydrogen,
alkyl, substituted alkyl, halide, cyano- or nitro-group, a hydrophilic group,
like amino, substituted amino, alkylamino, substituted alkylamino,
10 alkylammonium, substituted alkylammonium, carboxy, carboxylate,
carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted
alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or
unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo,
sulfino, sulfeno, sulfonate, sulfinate, sulfenate, sulfamoyl, sulfoxide,
15 phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate,
phosphinate or,

wherein within R1-R12 two adjacent Rs can form an aliphatic ring or a
substituted aliphatic ring, wherein the substituent is selected from hydrogen,
alkyl, substituted alkyl, halide, cyano- or nitro-group, a hydrophilic group,
like amino, substituted amino, alkylamino, substituted alkylamino,
20 alkylammonium, substituted alkylammonium, carboxy, carboxylate,
carboxylic acid ester, carbamoyl, hydroxy, substituted or unsubstituted
alkyloxy, substituted or unsubstituted aryloxy, sulfanyl, substituted or
unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, sulfo,
sulfino, sulfeno, sulfonate, sulfinate, sulfenate, sulfamoyl, sulfoxide,
25 phosphono, hydroxyphosphinoyl, hydroxyl-alkyl-phosphinoyl, phosphonate,
phosphinate,

wherein, if in any of R1-R13 a substitution is present, the substituent in R1-
R13 is each independently selected from a halide, cyano- or nitro-group, a
30 hydrophilic group, like an amino, alkylamino, alkylammonium, carboxy,
carboxylate, carboxylic acid ester, carbamoyl, hydroxy, alkyloxy,
arylalkyloxy, aryloxy, alkylaryloxy, polyethylenoxy, polypropylenoxy,
sulfanyl, alkylsulfonyl, arylsulfonyl, sulfo, sulfino, sulfeno, sulfonate,
sulfinate, sulfenate, sulfamoyl, sulfoxide, phosphono, hydroxyphosphinoyl,
35 hydroxyl-alkyl-phosphinoyl, phosphonate, phosphinate,

wherein alkyl is a linear or branched alkyl chain with a length of 1-20 carbon atoms or a heteroalkyl chain with the length of 1-20 atoms comprising 1-4 heteroatoms selected from O, N, P, and S, wherein aryl is a 5, 6, or 7 member aryl ring system, or a 5, 6, or 7 member heteroaryl ring system comprising 1-3 heteroatoms selected from O, S and N,

5

with the proviso that at least one of R1-R12 is sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, sulfino-alkyl, sulfmo-aryl, sulfmo-alkoxy, sulfino-aryloxy, sulfino, sulfeno-alkyl, sulfeno-aryl, sulfeno-alkoxy, sulfeno-aryloxy, sulfeno, sulfamoyl-alkyl, sulfamoyl-aryl, sulfamoyl-alkoxy, sulfamoyl-aryloxy, sulfamoyl, alkanesulfonyl-alkyl, alkanesulfonyl-aryl, alkanesulfonyl, arenesulfonyl-alkyl, or arenesulfonyl-aryl, or arenesulfonyl, sulfoamino-alkyl, sulfoamino-aryl, sulfoamino-alkoxy, sulfoamino-aryloxy, sulfoamino, sulfinoamino-alkyl, sulfinoamino-aryl, sulfinoamino-alkoxy, sulfinoamino-aryloxy, sulfinoamino, alkanesulfonylamino-alkyl, alkanesulfonylamino-aryl, alkanesulfonylamino-alkoxy, alkanesulfonylamino-aryloxy, alkanesulfonylamino, arenesulfonylamino-alkyl, arenesulfonylamino-aryl, arenesulfonylamino-alkoxy, arenesulfonylamino-aryloxy, arenesulfonylamino, alkanesulfinylamino-alkyl, alkanesulfinylamino-aryl, alkanesulfinylamino-alkoxy, alkanesulfinylamino-aryloxy, alkanesulfinylamino, arenesulfinylamino-alkyl, arenesulfinylamino-aryl, arenesulfinylamino-alkoxy, arenesulfinylamino-aryloxy, arenesulfinylamino, phosphono-alkyl, phosphono-aryl, phosphono-alkyloxy, phosphono-aryloxy, phosphono, hydroxyphosphinoyl-alkyl, hydroxyphosphinoyl-aryl, hydroxyphosphinoyl-alkyloxy, hydroxyphosphinoyl-aryloxy, hydroxyphosphinoyl, hydroxy-alkyl-phosphinoyl-alkyl, hydroxy-alkyl-phosphinoyl-aryl, hydroxy-alkyl-phosphinoyl-alkyloxy, hydroxy-alkyl-phosphinoyl-aryloxy, hydroxy-alkyl-phosphinoyl, phosphonoamino-alkyl, phosphonoamino-aryl, phosphonoamino-alkoxy, phosphonoamino-aryloxy, phosphonoamino, or, where chemically matching, a salt of the above described substituents.

30

35

2. The compound of claim 1, wherein at least one of R1 to R12 is sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, sulfamoyl-alkyl, sulfamoyl-aryl, sulfamoyl-alkoxy, sulfamoyl-aryloxy, sulfamoyl, alkanesulfonyl-alkyl, alkanesulfonyl-aryl, alkanesulfonyl, arenesulfonyl-alkyl, arenesulfonyl-aryl, arenesulfonyl, alkanesulfonylamino-alkyl, alkanesulfonylamino-aryl,

- alkanesulfonylamino-alkoxy, alkanesulfonylamino-aryloxy,
alkanesulfonylamino, arenesulfonylamino-alkyl, arenesulfonylamino-aryl,
arenesulfonylamino-alkoxy, arenesulfonylamino-aryloxy,
arenesulfonylamino, phosphono-alkyl, phosphono-aryl, phosphono-alkyloxy,
5 phosphono-aryloxy, phosphono, hydroxyphosphinoyl-alkyl,
hydroxyphosphinoyl-aryl, hydroxyphosphinoyl-alkyloxy,
hydroxyphosphinoyl-aryloxy, hydroxyphosphinoyl, hydroxy-alkyl-
phosphinoyl-alkyl, hydroxy-alkyl-phosphinoyl-aryl, hydroxy-alkyl-
phosphinoyl-alkyloxy, hydroxy-alkyl-phosphinoyl-aryloxy, hydroxy-alkyl-
10 phosphinoyl, or, where chemically matching, a salt of the above described
substituents.
3. The compound according to claim 1 or 2, wherein at least one of R1 to R12 is
sulfo-alkyl, sulfo-aryl, sulfo-alkoxy, sulfo-aryloxy, sulfo, or a salt thereof
(=sulfonate), wherein the counter ion is a cation from the group of alkali
15 metals.
4. The compound according to any of claims 1 to 3, wherein at least one of R1
to R12 is sulfo-alkyl, sulfo-alkoxy, sulfo, or a salt thereof (-sulfonate),
wherein the counter ion is a cation from the group of alkali metals.
5. The compound according to any of claims 1 to 4, wherein at least one of R1
20 to R12 is sulfo-methyl, sulfo-alkoxy with a C2 to C4 alkyl chain, or a salt
thereof (=sulfonate) wherein the counter ion is a cation from the group of
alkali metals.
6. The compound according to any of claims 1 to 5, wherein at least one of the
groups R1 to R12 is a sulfo group.
- 25 7. Use of a compound according to any of claims 1 to 6 in the manufacturing of
an electrochemiluminescent label based on iridium³⁺, comprising twice a
phenyl-phenanthridine derivative as defined via Formula I of any one of
claims 1 to 6 and a third ligand.
8. The use according to claim 7, wherein the third ligand is selected from the
30 group consisting of a derivative of picolinic acid, a derivative of azolyl
pyridine, a derivative of bipyridyl, a derivative of phenyl-pyridine, and a
derivative of phenylazole.

9. The use according to claim 8, wherein the third ligand is a derivative of picolinic acid.
10. The use according to claim 8, wherein the third ligand is a derivative of azolyl pyridine.
- 5 11. The use according to claim 8, wherein the third ligand is a derivative of bipyridyl.
12. The use according to claim 8, wherein the third ligand is a derivative of phenyl-pyridine.
13. The use according to claim 8, wherein the third ligand is a derivative of phenylazole.
- 10 14. A method for producing an electrochemiluminescent label the method comprising the steps of incubating an iridium dimer complex according to any of claims 1 to 6 with a third ligand in an organic solvent under inert gas atmosphere.
- 15 15. Use of a compound according to any of claims 1 to 6 as a starting material in the manufacturing of an electrochemiluminescent label.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2013/002324

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07F15/00 H01L51/50
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07F H01L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ALTUNTAS, ESRA ET AL: "Determi nati on of the rel ati ve ligand-bi nding strengths in heterol epti c Ir111 complexes by ESI-Q-TOF tandem mass spectrometry" , JOURNAL OF MASS SPECTROMETRY , 47(1) , 34-40 CODEN: JMSPFJ; ISSN: 1076-5174, vol . 47, 28 December 2011 (2011-12-28) , pages 34-40, XP002688231 , page 34 f i r s t paragraph ; complex 2 scheme 1 page 36.</p> <p style="text-align: center;">-----</p>	1-14

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 20 September 2013	Date of mailing of the international search report 30/09/2013
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Bourghi da, E
--	--